Compare Okta, Inc. (OKTA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Summit Therapeutics Inc — how do they compare? Okta, Inc. trades at $172.7 (market cap $30.20B), while Summit Therapeutics Inc trades at $17.58 (market cap $13.98B). The key difference: Okta, Inc. is far larger — about 2.2× Summit Therapeutics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| OKTA | SMMT | |
|---|---|---|
Market Cap | $30.20B | $13.98B |
Sector | Technology | Health |
52-Week High | $173.04 | $26.38 |
52-Week Low | $62.93 | $12.43 |
Enterprise Value | $27.95B | $13.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $167.60, down 1.76% on the day but up 94% year-to-date, driven by strong earnings beats and AI-driven demand for cybersecurity. The stock is in a bullish technical trend with support at $166 and resistance at $170. Fundamentals show improving profitability, with Q2 2026 EPS of $1.05 beating estimates, revenue growth accelerating to $2.61 billion in 2025, and a net income margin turning positive to 9.63% in 2026 projections. Analyst sentiment remains overwhelmingly positive with a $181.61 consensus target.
The outlook for OKTA is bullish, supported by robust earnings momentum, AI security adoption, and strong institutional backing. Key opportunities include expanding AI-agent security offerings and sustained revenue growth. Risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and insider selling activity. The stock's proximity to its 52-week high suggests cautious entry points may be warranted despite positive catalysts.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
